Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication ... Zepbound’s new indication highlights its broader therapeutic potential.

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

Consumers who take copies of the popular weight loss and diabetes ... said Dae Lee, a New Jersey attorney who represents pharmacies. The branded drugs, Zepbound and Mounjaro, are typically much ...